Research programme: paclitaxel nano-emulsion formulation - ADVENTRX Pharmaceuticals

Drug Profile

Research programme: paclitaxel nano-emulsion formulation - ADVENTRX Pharmaceuticals

Alternative Names: ANX 513; BTH 013; SDP-013

Latest Information Update: 30 Oct 2008

Price : $50

At a glance

  • Originator ADVENTRX Pharmaceuticals
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 30 Jan 2007 Preclinical development is ongoing
  • 28 Apr 2006 SD Pharmaceuticals has been acquired by ADVENTRX Pharmaceuticals
  • 28 Mar 2006 Preclinical trials in Ovarian Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top